{
  "abstract": "Background: Bone disease is a common manifestation of multiple myeloma. Although anti-resorptive therapy is recommended by guidelines, implementation can be variable. We sought to evaluate practice patterns for myeloma bone disease management and to identify opportunities for harmonization.\n\nMethods: An online survey was distributed to clinicians who see patients with multiple myeloma at medical centers affiliated with the Big Ten Cancer Research Consortium. Anonymous responses were collected regarding self-reported demographics, as well as practice patterns regarding preferred antiresorptive agent, dosing, duration of therapy, therapy modifications, vitamin and mineral supplementation, dental restrictions, and management at relapse.\n\nResults: A total of 100 responses were collected from 11 different academic institutions and their community-affiliated sites. Respondents were predominantly physicians (74%) working in an academic setting (77%), with variable time practicing independently and number of myeloma patients seen per year. Most respondents (89%) reported using zoledronic acid as the preferred agent, with every 4 weeks as the most common frequency (for zoledronic acid 70%, denosumab 64%), with most administering therapy for 2 years (72%). Most clinical scenarios did not affect anti-resorptive choice at diagnosis, except for severe renal insufficiency. Dental recommendations were heterogeneous. There was low utilization of biomarkers to guide management decisions.\n\nConclusion: Our survey suggests that at the time of diagnosis, most clinicians administer appropriate supportive care for myeloma bone disease. Further study is needed to help unify practice patterns in the relapsed setting, when dental care is suboptimal, and when it is appropriate to tailor such therapy.",
  "abstract_shown": true,
  "affiliations": [
    "University of Wisconsin-Carbone Cancer Center, University of Wisconsin-Madison",
    "Department of Medicine, Michigan State University",
    "Department of Medicine, University of Minnesota",
    "Division of Hematology and Oncology, United States, University of Washington",
    "Department of Hematology-Oncology, Indiana University",
    "Department of Internal Medicine, University of Iowa",
    "Department of Internal Medicine, Ohio State University",
    "Division of Hematology, University of Nebraska Medical Center",
    "Division of Hematology/Oncology, University of Illinois-Chicago",
    "Department of Internal Medicine, Penn State Cancer Institute, Pennsylvania State University",
    "Department of Internal Medicine, University of Michigan"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 14,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Timothy Schmidt"
    },
    {
      "affs": [
        1
      ],
      "name": "Ryan Gennette"
    },
    {
      "affs": [
        1
      ],
      "name": "Craig Cole"
    },
    {
      "affs": [
        2
      ],
      "name": "Aimee Merino"
    },
    {
      "affs": [
        3
      ],
      "name": "Danai Dima"
    },
    {
      "affs": [
        4
      ],
      "name": "Malini Surapaneni"
    },
    {
      "affs": [
        5
      ],
      "name": "Hira Shaikh"
    },
    {
      "affs": [
        6
      ],
      "name": "Elvira Umyarova"
    },
    {
      "affs": [
        7
      ],
      "name": "Christopher D’Angelo"
    },
    {
      "affs": [
        8
      ],
      "name": "Matias Sanchez"
    },
    {
      "affs": [
        9
      ],
      "name": "Kevin Rakszawski"
    },
    {
      "affs": [
        0
      ],
      "name": "Natalie Callander"
    },
    {
      "affs": [
        10
      ],
      "name": "Matthew Pianko"
    },
    {
      "affs": [
        4
      ],
      "name": "Attaya Suvannasankha"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/1mzc6cx7avxsw.bib",
  "cited_by": 0,
  "doi": "10.3389/fonc.2026.1948667",
  "fulltext_url": "https://europepmc.org/articles/PMC13713382",
  "id": "1mzc6cx7avxsw",
  "issns": [
    "2234-943X"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1948667/full",
  "language": "eng",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Research"
    ],
    [
      "openalex",
      "2720|Multiple Myeloma Research and Treatments"
    ]
  ],
  "openalex": "W7221765814",
  "pdf_url": "https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1948667/pdf",
  "pmcid": "PMC13713382",
  "pmid": "42952551",
  "published": "2026-10-14",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/1mzc6cx7avxsw.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:13Z",
      "native_id": "10.3389/fonc.2026.1948667",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1948667/full"
    },
    {
      "first_seen": "2026-10-31T00:20:34Z",
      "native_id": "MED:42952551",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42952551"
    },
    {
      "first_seen": "2026-10-31T12:23:56Z",
      "native_id": "PMC13713382",
      "source": "pmc",
      "url": "https://doi.org/10.3389/fonc.2026.1948667"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "issn:2234-943X",
      "subfield": "oncology"
    }
  ],
  "title": "Practice patterns in myeloma bone disease: a multi-center survey",
  "title_text": "Practice patterns in myeloma bone disease: a multi-center survey",
  "type": "peer-reviewed",
  "updated_at": "2026-11-01T12:21:03Z",
  "url": "https://research.draconitic.com/paper/1mzc6cx7avxsw",
  "venue": "Frontiers in Oncology",
  "versions": []
}